Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -140.55% is 377% below its 5-year average of -29.45%, near the low end of its 5-year range (-140.55%–-14.92%).
As of the fiscal period ended Tuesday, June 30, 2026. 51.86% below its 12-month average of -92.55%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -140.55%.
RETURN ON EQUITY (ROE)
-140.55%
RETURN ON EQUITY (ROE) AVG TTM
-92.55%
RETURN ON EQUITY (ROE) AVG 3Y
-42.89%
RETURN ON EQUITY (ROE) AVG 5Y
-29.45%
RETURN ON EQUITY (ROE) AVG 10Y
-78.38%
RETURN ON EQUITY (ROE) AVG 15Y
-88.50%
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-51.86%
CURRENT VS 3Y AVG
-227.69%
CURRENT VS 5Y AVG
-377.30%
CURRENT VS 10Y AVG
-79.33%
CURRENT VS 15Y AVG
-58.81%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-290.36%
vs the sector median at left
Atossa Therapeutics, Inc.
Market Cap
$24.44M
Return on Equity (ROE)
-140.55%
TTM Avg
-92.55%
3Y Avg
-42.89%
5Y Avg
-29.45%
Market Cap
$25.48M
Return on Equity (ROE)
-76.82%
TTM Avg
-235.52%
3Y Avg
-335.24%
5Y Avg
-272.42%
Market Cap
$21.90M
Return on Equity (ROE)
-40.40%
TTM Avg
-55.95%
3Y Avg
-53.10%
5Y Avg
-83.38%
Market Cap
$27.31M
Return on Equity (ROE)
-111.81%
TTM Avg
-29.10%
3Y Avg
-257.52%
5Y Avg
159.26%
Market Cap
$20.93M
Return on Equity (ROE)
-2067.81%
TTM Avg
-13234.78%
3Y Avg
-6645.16%
5Y Avg
-6645.16%
Market Cap
$28.43M
Return on Equity (ROE)
-124.64%
TTM Avg
-100.64%
3Y Avg
-80.07%
5Y Avg
-67.08%
Market Cap
$18.82M
Return on Equity (ROE)
-117.98%
TTM Avg
-84.94%
3Y Avg
-64.05%
5Y Avg
-76.29%
Market Cap
$18.77M
Return on Equity (ROE)
N/A
TTM Avg
-3014.83%
3Y Avg
-1589.49%
5Y Avg
-1032.64%
Market Cap
$30.65M
Return on Equity (ROE)
-132.18%
TTM Avg
-94.77%
3Y Avg
-38.62%
5Y Avg
-46.78%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | $24.44M | -140.55% | -92.55% | -42.89% | -29.45% |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.48M | -76.82% | -235.52% | -335.24% | -272.42% |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | -40.40% | -55.95% | -53.10% | -83.38% |
| GridAI Technologies Corp. (GRDX)vs › | $27.31M | -111.81% | -29.10% | -257.52% | 159.26% |
| Actuate Therapeutics Inc (ACTU)vs › | $20.93M | -2067.81% | -13234.78% | -6645.16% | -6645.16% |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | -124.64% | -100.64% | -80.07% | -67.08% |
| Cosmos Health Inc. (COSM)vs › | $18.82M | -117.98% | -84.94% | -64.05% | -76.29% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | N/A | -3014.83% | -1589.49% | -1032.64% |
| CervoMed Inc. (CRVO)vs › | $30.65M | -132.18% | -94.77% | -38.62% | -46.78% |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | -120.40% | -43.89% | -83.08% | -65.54% |
ROE
-140.5%
ROA
-116.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -140.55% |
| 2026-03-31 | -123.47% |
| 2025-12-31 | -88.35% |
| 2025-09-30 | -60.62% |
| 2025-06-30 | -49.78% |
| 2025-03-31 | -40.33% |
| 2024-12-31 | -35.68% |
| 2024-09-30 | -36.52% |
| 2024-06-30 | -32.32% |
| 2024-03-31 | -34.62% |
| 2023-12-31 | -33.06% |
| 2023-09-30 | -30.36% |
| 2023-06-30 | -30.14% |
| 2023-03-31 | -25.12% |
| 2022-12-31 | -22.85% |
| 2022-09-30 | -19.62% |
| 2022-06-30 | -16.50% |
| 2022-03-31 | -16.17% |
| 2021-12-31 | -14.92% |
| 2021-09-30 | -16.45% |
| 2021-06-30 | -14.96% |
| 2021-03-31 | -13.18% |
| 2020-12-31 | -65.62% |
| 2020-09-30 | -131.32% |
| 2020-06-30 | -152.34% |
| 2020-03-31 | -147.88% |
| 2019-12-31 | -131.04% |
| 2019-09-30 | -111.20% |
| 2019-06-30 | -95.28% |
| 2019-03-31 | -69.78% |
| 2018-12-31 | -129.53% |
| 2018-09-30 | -107.10% |
| 2018-06-30 | -75.14% |
| 2018-03-31 | -157.68% |
| 2017-12-31 | -117.06% |
| 2017-09-30 | -337.65% |
| 2017-06-30 | -223.43% |
| 2017-03-31 | -375.88% |
| 2016-12-31 | -205.64% |
| 2016-09-30 | -162.65% |
| 2016-06-30 | -553.02% |
| 2016-03-31 | -390.98% |
| 2015-12-31 | -421.20% |
| 2015-09-30 | -183.37% |
| 2015-06-30 | -118.39% |
| 2015-03-31 | -151.52% |
| 2014-12-31 | -154.32% |
| 2014-09-30 | -76.17% |
| 2014-06-30 | -64.96% |
| 2014-03-31 | -52.84% |
| 2013-12-31 | -101.73% |
| 2013-09-30 | -84.34% |
| 2013-06-30 | -89.05% |
| 2013-03-31 | -85.42% |
| 2012-12-31 | -98.15% |
| 2012-09-30 | -134.63% |
| 2012-03-31 | -732.82% |
| 2011-12-31 | -222.27% |
| 2011-09-30 | -95.16% |
